Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

68 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-05-31

Study Completion Date

2007-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will examine the safety and effectiveness of the antipsychotic drug olanzapine in children and adolescents with bipolar disorder or psychosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders

NCT00001656

Childhood Schizophrenia Psychotic Disorder Schizophrenia

COMPLETED PHASE4

Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder

NCT00050206

Bipolar Disorder

COMPLETED PHASE4

Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder

NCT00113594

Schizophrenia Bipolar Disorder

COMPLETED PHASE3

Short Term Rescue Study of Olanzapine

NCT00186017

Bipolar Disorder

COMPLETED PHASE4

Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed

NCT00618748

Bipolar I Disorder

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Numerous advancements in mental health treatment have been made over the past decade. Unfortunately, these advancements have focused on adults and have not been fully extended to children and adolescents. With limited pediatric information on the pharmacokinetics and pharmacodynamics for drugs used to treat mental health problems, psychiatrists are prescribing drugs for children using data extrapolated from adults, which may lead to potentially life-threatening results. Olanzapine is widely prescribed to treat both children and adults. This study will determine the safety and effectiveness of olanzapine in children and adolescents with mental health disorders. The study will also compare the effects of gender, development, body composition, and metabolic genotype and phenotype on how olanzapine works.

All participants will receive olanzapine for up to 8 weeks. Blood collection will occur at each weekly study visit. On Visit 1, participants will receive their first dose of olanzapine and repeated blood collection will occur every hour for 24 hours. Blood collection will be used to determine the time it takes for olanzapine to be absorbed into the body, its duration of action, the extent of its distribution in the body, the manner in which it is excreted from the body, and its effects on organs of the body.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bipolar Disorder Psychotic Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Olanzapine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of bipolar disorder with mania, mixed mania, or psychosis not otherwise specified
* Meet certain laboratory result requirements
* Have taken either lithium or valproate for 4 weeks or longer with no or only partial response
* Parent or guardian willing to provide informed consent

Exclusion Criteria

* History of other serious unstable illness requiring medication
* Diabetes mellitus
* Abnormal physical examination and electrocardiogram (EKG) results
* At risk for suicide or homicide (based on an assessment of suicidal history, intent or plan, mental state, mood, and substance use)
* IQ less than 65
* History of organic brain disease or seizure disorder
* Recent exposure to an infectious disease, such as tuberculosis (TB) or meningitis
* Current use of drugs that may interfere with the metabolism of olanzapine and unwilling to discontinue use during the study
* Body mass index (BMI) less than the 5th OR greater than the 95th percentile for age and gender
* History of smoking within 1 year prior to study entry
* Pregnancy or breastfeeding

Minimum Eligible Age

6 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No